Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a vaccine for Covid constituted “the biggest success that anyone could dream of having,” he said, which will undoubtedly be his legacy at the company.

Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.

U.S. drugmaker Pfizer raised its full-year profit forecast on Tuesday after reporting better-than-expected results for the second quarter, boosted by strong demand for its heart disease drug, Vyndaqel,

The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his planned tariffs on pharmaceuticals.